Included in the formulation
Pharmacodynamics:
Anticoagulant of direct action, enhances the blockade of antithrombin-activated III factors of blood coagulation, inactivates factor Xa, inhibits coagulation and formation of a blood clot. Accelerates the formation of complexes of thrombin with antithrombin III, slowing the transformation of fibrinogen into fibrin and the organization of a thrombus. Reduces the aggregation of platelets.
Pharmacokinetics:
After subcutaneous administration, the maximum concentration in the blood plasma is reached after 30-60 minutes.
The therapeutic effect persists for 20 hours after the injection. Partially destroyed by heparinase. It does not penetrate the blood-brain and placental barriers.
The half-life is 60-90 minutes. Elimination of the kidneys unchanged.
Indications:
It is used for the treatment and prevention of thrombosis and thromboembolism.
IX.I70-I79.I74 Embolism and thrombosis of the arteries
IX.I80-I89.I82 Embolism and thrombosis of other veins
Contraindications:
Conditions and diseases, accompanied by a decrease in blood clotting: thrombocytopenia, a deficiency of coagulation factors, hemorrhagic diathesis. Gastric and duodenal ulcers, acute bacterial endocarditis, hemorrhagic stroke, ulcerative colitis, individual intolerance, children under 3 years old.
Carefully:
Renal and hepatic insufficiency.
Pregnancy and lactation:
Recommendations for FDA - Category C. It is used in pregnancy in cases where the potential benefit of the drug exceeds the possible risk to the fetus. Contraindicated during lactation.
Dosing and Administration:Use in children
0.2-0.3 ml.
Adults
Subcutaneously with thromboembolism: 0.1 ml (2500 IU), after 12 hours - at the same or adjusted dose after monitoring the coagulation time, then every 12 hours at the dose selected for the second injection.
For the purpose of prophylaxis: subcutaneously, 0.2 ml (5000 IU) 2-3 times a day or 0.3 ml (7500 IU) 2 times a day.
The highest daily dose: 0.6 ml (15000 IU).
The highest single dose: 0.3 ml (7500 IU).
Side effects:
Blood coagulation system: thrombocytopenia.
Local reactions: necrosis or bruising at the injection site.
Allergic reactions.
Overdose:
Bleeding.
Treatment is symptomatic. Slow intravenous administration of protamine (antagonist).
Interaction:
The risk of bleeding increases with simultaneous use with salicylates, indirect coagulants, glucocorticoids, nonsteroidal anti-inflammatory drugs, antiaggregants.
Special instructions:
Monitoring the amount of peripheral blood platelets.